Drugs / BinD19
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03156101 | Mar 2017 → May 2021 | B-cell acute lymphoblastic leukemia | Shenzhen BinDeBio Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03265106 | Nov 2016 → May 2021 | B-cell childhood acute lymphoblastic leukemia | Shenzhen BinDeBio Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BinD19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03156101 ↗ |
| Modality | Cell therapy | “Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future...” NCT03156101 ↗ |
| Route | Intravenous | “administered as an IV infusion” NCT03156101 ↗ |
| Target | CD19 | “BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector)” NCT03156101 ↗ |